Pentacarinat and Ceftazidime drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Pentacarinat (pentamidine isethionate) and Ceftazidime (ceftazidime). Common drug interactions include stevens-johnson syndrome among females and haemorrhage among males.

The phase IV clinical study analyzes what interactions people have when they take Pentacarinat and Ceftazidime. It is created by eHealthMe based on reports of 26 people who take the same drugs from the FDA, and is updated regularly.

What is Pentacarinat?

Pentacarinat has active ingredients of pentamidine isethionate. eHealthMe is studying from 1,546 Pentacarinat users. Check the latest studies of Pentacarinat.

What is Ceftazidime?

Ceftazidime has active ingredients of ceftazidime. eHealthMe is studying from 10,327 Ceftazidime users. Check the latest studies of Ceftazidime.



On Jul, 15, 2026

26 people who take Pentacarinat and Ceftazidime together, and have interactions are studied.

Pentacarinat and Ceftazidime drug interactions.

What are the common drug interactions of Pentacarinat and Ceftazidime, by gender? *:

female:

  1. Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)
  2. Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)
  3. Rash maculo-papular (red area on the skin that is covered with small confluent bumps)
  4. Acute circulatory failure (shock)
  5. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  6. Cough
  7. Depressed level of consciousness
  8. Dyspnoea (difficult or laboured respiration)
  9. Electrocardiogram qt prolonged
  10. Epidermal necrolysis (skin condition that is usually caused by a reaction to drugs)

male:

  1. Haemorrhage (bleeding)
  2. Loss of consciousness
  3. Haemoglobin decreased
  4. Hyperglycaemia (high blood sugar)
  5. Hypocalcaemia (levels of calcium in blood serum are abnormally low)
  6. Hypochloraemia (electrolyte disturbance in which there is an abnormally low level of the chloride ion in the blood)
  7. Malnutrition (a condition that results from eating a diet in which certain nutrients are lacking)
  8. Pyrexia (fever)
  9. Renal failure acute (rapid kidney dysfunction)
  10. Thrombocytopenia (decrease of platelets in blood)

What are the common drug interactions of Pentacarinat and Ceftazidime, by age (0-1 to 60+)? *:

0-1:

  1. Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)
  2. Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)

2-9:

  1. Blood alkaline phosphatase nos increased
  2. Haemoglobin decreased
  3. Hypochloraemia (electrolyte disturbance in which there is an abnormally low level of the chloride ion in the blood)
  4. Thrombocytopenia (decrease of platelets in blood)
  5. Aspartate aminotransferase increased
  6. Blood urea increased
  7. Hyperglycaemia (high blood sugar)
  8. Hypocalcaemia (levels of calcium in blood serum are abnormally low)
  9. Pneumonia
  10. Pyrexia (fever)

10-19:

n/a

20-29:

  1. Renal failure acute (rapid kidney dysfunction)
  2. Overdose

30-39:

  1. Oedematous pancreatitis (interstitial inflammation and swelling of pancreas)
  2. Rash maculo-papular (red area on the skin that is covered with small confluent bumps)

40-49:

n/a

50-59:

  1. Stevens-johnson syndrome (an immune-complex-mediated hypersensitivity disorder. it ranges from mild skin and mucous membrane lesions to a severe)
  2. Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)
  3. Blister (small pocket of fluid within the upper layers of the skin caused by forceful rubbing (friction), burning, freezing, chemical exposure)
  4. Epidermal necrolysis (skin condition that is usually caused by a reaction to drugs)
  5. Gastroenteritis (inflammation of stomach and intestine)
  6. Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
  7. Mucosal inflammation (infection of mucous membrane)
  8. Pneumonia
  9. Pyrexia (fever)
  10. Rash erythematous (redness of the skin)

60+:

  1. Haemorrhage (bleeding)
  2. Loss of consciousness
  3. Bradycardia (abnormally slow heart action)
  4. Cough
  5. Depressed level of consciousness
  6. Dyspnoea (difficult or laboured respiration)
  7. Electrocardiogram qt prolonged
  8. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  9. Lymphocytosis (an increase in the number or proportion of lymphocytes in the blood)
  10. Pneumonia

What are the existing conditions these people have? *

  1. Pain: 12 people, 46.15%
  2. Hyperglycemia (high blood sugar): 12 people, 46.15%
  3. Hyponatremia (abnormally low level of sodium in the blood; associated with dehydration): 10 people, 38.46%
  4. Dyspnea (difficult or laboured breathing): 8 people, 30.77%
  5. Hypoalbuminaemia (levels of albumin in blood serum are abnormally low): 8 people, 30.77%
  6. Pneumonia: 7 people, 26.92%
  7. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 7 people, 26.92%
  8. Insomnia (sleeplessness): 6 people, 23.08%
  9. Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood): 6 people, 23.08%
  10. Hypokalemia (low potassium): 6 people, 23.08%

* Approximation only. Some reports may have incomplete information.

Do you take Pentacarinat and Ceftazidime?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Pentacarinat and Ceftazidime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Pentacarinat:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ceftazidime:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pentacarinat and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ceftazidime and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on pentamidine isethionate and ceftazidime (the active ingredients of Pentacarinat and Ceftazidime, respectively), and Pentacarinat and Ceftazidime (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: